Rolapitant Hydrochloride Monohydrate structure
|
Common Name | Rolapitant Hydrochloride Monohydrate | ||
---|---|---|---|---|
CAS Number | 914462-92-3 | Molecular Weight | 554.953 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C25H29ClF6N2O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Rolapitant Hydrochloride MonohydrateRolapitant hydrochloride hydrate (SCH619734 hydrochloride hydrate) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant hydrochloride hydrate does not interact with CYP3A4. Rolapitant hydrochloride hydrate shows potent anti-emetic activity in a ferret emesis model[1][2]. |
Name | (5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one,hydrate,hydrochloride |
---|---|
Synonym | More Synonyms |
Description | Rolapitant hydrochloride hydrate (SCH619734 hydrochloride hydrate) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant hydrochloride hydrate does not interact with CYP3A4. Rolapitant hydrochloride hydrate shows potent anti-emetic activity in a ferret emesis model[1][2]. |
---|---|
Related Catalog | |
Target |
human NK1:0.66 nM (Ki) gerbil NK1:0.13 nM (Ki) guinea pig NK1:0.72 nM (Ki) monkey NK1:2.5 nM (Ki) rabbit NK1:31.7 nM (Ki) rat NK1:78.6 nM (Ki) mouse NK1:60.4 nM (Ki) |
In Vitro | Rolapitant hydrochloride hydrate 对人类 NK2 和 NK3 亚型的选择性超过 1000 倍,并且对人类、豚鼠、沙鼠和猴子 NK1 受体的亲和力优于大鼠、小鼠和兔[1]. Rolapitant hydrochloride hydrate (1-1000 nM) 在表达人 NK1 受体的 CHO 细胞中以浓度依赖性和竞争性方式抑制 GR-73632 (一种 NK1 受体激动剂) 诱导的钙流出[1]。 |
In Vivo | Rolapitant hydrochloride hydrate (0.03-1 mg/kg for PO, 0.3-1 mg/kg for IV; single dosage) 减弱蒙古沙鼠中 GR-73632 (HY-P1192) 诱导的足部敲击反应[1]。 Rolapitant hydrochloride hydrate (0.03-1 mg/kg; PO; single dosage; observed for 72 h) 阻断雪貂中由阿扑吗啡和 cisplatin (HY-17394) 引起的急性呕吐[1]。 Animal Model: Female Mongolian Gerbils (30-60 g; anesthetized by inhalation of an oxygen:isofluorane mixture after 4 h PO or immediately after IV, then injected with 5 μl of 3 pmol solution of GR-73632 via ICV)[1] Dosage: 0.03, 0.1, 0.3 and 1 mg/kg for PO, 0.3 and 1 mg/kg for IV Administration: PO or IV, single dosage Result: Attenuated dose-dependently the GR-73632-induced foot-tapping response when administered PO 4 h before testing, with an ID90 of 0.3 mg/kg, and the inhibition in foot tapping for at least 24 h. Blocked dose-dependently the foot tapping induced by GR-73632 when administered IV, with complete blockade observed at 1 mg/kg. Animal Model: Ferrets (treated with subcutaneous administration of 0.125 mg/kg apomorphine or intraperitoneal administration of 10 mg/kg cisplatin)[1] Dosage: 0.03, 0.1, 0.3 and 1 mg/kg Administration: PO; single dosage; observed for 72 h Result: Blocked dose-dependently acute emesis induced by both apomorphine and cisplatin in ferrets. Produced a robust decrease in retches and vomits in ferrets that was maintained throughout the 72 h observation period. |
References |
Molecular Formula | C25H29ClF6N2O3 |
---|---|
Molecular Weight | 554.953 |
Exact Mass | 554.177063 |
PSA | 63.08000 |
LogP | 7.07190 |
rolapitant hydrochloride hydrate |
Rolapitant hydrochloride |
UNII:57O5S1QSAQ |
(5S,8S)-8-({(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one hydrochloride hydrate |
Varubi |
1,7-Diazaspiro[4.5]decan-2-one, 8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-, (5S,8S)-, hydrochloride, hydrate (1:1:1) |
UNII-57O5S1QSAQ |
Rolapitant HCl |
Rolapitant Hydrochloride Monohydrate |